{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:13:20Z","timestamp":1790507600227,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1124\/mol.119.117259","type":"journal-article","created":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T06:55:10Z","timestamp":1565420110000},"page":"475-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations"],"prefix":"10.1016","volume":"96","author":[{"given":"Mandeep","family":"Atwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-7448","authenticated-orcid":false,"given":"Rebecca L.","family":"Swan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6857-624X","authenticated-orcid":false,"given":"David C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-9362","authenticated-orcid":false,"given":"Lyle","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8606-0447","authenticated-orcid":false,"given":"Ian G.","family":"Cowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1921-5947","authenticated-orcid":false,"given":"Caroline A.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.119.117259_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.116.106054","article-title":"Myeloperoxidase enhances etoposide and mitoxantrone-mediated DNA damage: a target for myeloprotection in cancer chemotherapy","volume":"91","author":"Atwal","year":"2017","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.119.117259_bib2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0006-291X(90)92156-T","article-title":"Structure and partial amino acid sequence of calf thymus DNA topoisomerase II: comparison with other type II enzymes","volume":"170","author":"Austin","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/mol.119.117259_bib3","first-page":"1886","article-title":"Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues","volume":"58","author":"Binaschi","year":"1998","journal-title":"Cancer Res"},{"key":"10.1124\/mol.119.117259_bib4","first-page":"5969","article-title":"DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA","volume":"49","author":"Bodley","year":"1989","journal-title":"Cancer Res"},{"key":"10.1124\/mol.119.117259_bib5","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1021\/bi00063a015","article-title":"Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II","volume":"32","author":"Capranico","year":"1993","journal-title":"Biochemistry"},{"key":"10.1124\/mol.119.117259_bib6","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1093\/nar\/18.22.6611","article-title":"Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin","volume":"18","author":"Capranico","year":"1990","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/mol.119.117259_bib7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1021\/bi00454a033","article-title":"Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity","volume":"29","author":"Capranico","year":"1990","journal-title":"Biochemistry"},{"key":"10.1124\/mol.119.117259_bib8","doi-asserted-by":"crossref","first-page":"13560","DOI":"10.1016\/S0021-9258(18)90729-5","article-title":"Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II","volume":"259","author":"Chen","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.119.117259_bib9","doi-asserted-by":"crossref","first-page":"10629","DOI":"10.1073\/pnas.1832879100","article-title":"Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187","volume":"100","author":"Classen","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.119.117259_bib10","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1093\/nar\/gkn439","article-title":"Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations","volume":"36","author":"Coldwell","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/mol.119.117259_bib11","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3390\/ijerph9062075","article-title":"Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents","volume":"9","author":"Cowell","year":"2012","journal-title":"Int J Environ Res Public Health"},{"key":"10.1124\/mol.119.117259_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/mutage\/geq094","article-title":"An overview of the visualisation and quantitation of low and high MW DNA adducts using the trapped in agarose DNA immunostaining (TARDIS) assay","volume":"26","author":"Cowell","year":"2011","journal-title":"Mutagenesis"},{"key":"10.1124\/mol.119.117259_bib13","first-page":"2","article-title":"Doxorubicin cardiotoxicity and target cells: a broader perspective","volume":"2","author":"De Angelis","year":"2016","journal-title":"Cardiooncology"},{"key":"10.1124\/mol.119.117259_bib14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/nbt.2005","article-title":"SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells","volume":"29","author":"Dubois","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1124\/mol.119.117259_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-003-0701-1","article-title":"Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity","volume":"53","author":"Errington","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/mol.119.117259_bib16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0026-895X(24)12397-8","article-title":"Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation","volume":"56","author":"Errington","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.119.117259_bib17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/med.21364","article-title":"Mitoxantrone, more than just another topoisomerase II poison","volume":"36","author":"Evison","year":"2016","journal-title":"Med Res Rev"},{"key":"10.1124\/mol.119.117259_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3727\/095535491820873308","article-title":"DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin","volume":"3","author":"Ferrazzi","year":"1991","journal-title":"Cancer Commun"},{"key":"10.1124\/mol.119.117259_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10637-016-0388-x","article-title":"Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase II\u03b2 activity and cardiac function in a chronic rabbit model","volume":"34","author":"Frank","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1124\/mol.119.117259_bib20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.119.117259_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.115.228650","article-title":"Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase II targeting agent with cellular selectivity for the topoisomerase II\u03b1 Isoform","volume":"356","author":"Hasinoff","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.119.117259_bib22","doi-asserted-by":"crossref","first-page":"38590","DOI":"10.1074\/jbc.M112.377903","article-title":"Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons","volume":"287","author":"Huelsenbeck","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.119.117259_bib23","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1021\/acschembio.5b00268","article-title":"Mitochondrial targeting of doxorubicin eliminates nuclear effects associated with cardiotoxicity","volume":"10","author":"Jean","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1124\/mol.119.117259_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood.V77.5.1080.1080","article-title":"NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3)","volume":"77","author":"Lanotte","year":"1991","journal-title":"Blood"},{"key":"10.1124\/mol.119.117259_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2015.12.015","article-title":"Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II","volume":"103","author":"Lee","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.119.117259_bib26","doi-asserted-by":"crossref","first-page":"13510","DOI":"10.1016\/S0021-9258(18)80026-6","article-title":"Single strand DNA cleavage reaction of duplex DNA by Drosophila topoisomerase II","volume":"264","author":"Lee","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.119.117259_bib27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nprot.2012.150","article-title":"Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt\/\u03b2-catenin signaling under fully defined conditions","volume":"8","author":"Lian","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1124\/mol.119.117259_bib28","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.119.117259_bib29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1021\/bi00301a024","article-title":"Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship","volume":"23","author":"Long","year":"1984","journal-title":"Biochemistry"},{"key":"10.1124\/mol.119.117259_bib30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0026-895X(25)15053-0","article-title":"Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy","volume":"25","author":"Lown","year":"1984","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.119.117259_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"key":"10.1124\/mol.119.117259_bib32","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1124\/mol.119.117259_bib33","doi-asserted-by":"crossref","first-page":"25333","DOI":"10.1038\/srep25333","article-title":"Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes","volume":"6","author":"Maillet","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/mol.119.117259_bib34","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.5b00473","article-title":"Differential targeting of human topoisomerase II isoforms with small molecules","volume":"58","author":"Mariani","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/mol.119.117259_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-291X(84)90454-6","article-title":"Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26","volume":"122","author":"Minocha","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/mol.119.117259_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1124\/mol.119.117259_bib37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1432-1033.1997.00307.x","article-title":"Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells","volume":"245","author":"Montaudon","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1124\/mol.119.117259_bib38","doi-asserted-by":"crossref","first-page":"Unit3.31","DOI":"10.1002\/0471141755.ph0303s57","article-title":"Topoisomerase assays","volume":"57","author":"Nitiss","year":"2012","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1124\/mol.119.117259_bib39","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0026-895X(24)12421-2","article-title":"Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha","volume":"58","author":"Patel","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.119.117259_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"key":"10.1124\/mol.119.117259_bib41","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling","volume":"14","author":"Reichardt","year":"2018","journal-title":"Future Oncol"},{"key":"10.1124\/mol.119.117259_bib42","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1073\/pnas.91.5.1781","article-title":"Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp","volume":"91","author":"Roca","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.119.117259_bib43","first-page":"3844","article-title":"Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance","volume":"49","author":"Sinha","year":"1989","journal-title":"Cancer Res"},{"key":"10.1124\/mol.119.117259_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mrfmmm.2008.03.005","article-title":"Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone","volume":"641","author":"Smart","year":"2008","journal-title":"Mutat Res"},{"key":"10.1124\/mol.119.117259_bib45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/mol.119.117259_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/mutage\/12.1.29","article-title":"Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations","volume":"12","author":"Suzuki","year":"1997","journal-title":"Mutagenesis"},{"key":"10.1124\/mol.119.117259_bib47","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1158\/0008-5472.CAN-05-3410","article-title":"Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death","volume":"66","author":"Swift","year":"2006","journal-title":"Cancer Res"},{"key":"10.1124\/mol.119.117259_bib48","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"10.1124\/mol.119.117259_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.stem.2012.09.013","article-title":"Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes","volume":"12","author":"Tohyama","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1124\/mol.119.117259_bib50","doi-asserted-by":"crossref","first-page":"23711","DOI":"10.1074\/jbc.M803936200","article-title":"NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform","volume":"283","author":"Toyoda","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.119.117259_bib51","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1006\/bbrc.1997.7021","article-title":"Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents","volume":"236","author":"Tuteja","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1124\/mol.119.117259_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003917.pub2","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","author":"van Dalen","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/mol.119.117259_bib53","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrm3228","article-title":"All tangled up: how cells direct, manage and exploit topoisomerase function","volume":"12","author":"Vos","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/mol.119.117259_bib54","first-page":"3591","article-title":"Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast","volume":"53","author":"Wasserman","year":"1993","journal-title":"Cancer Res"},{"key":"10.1124\/mol.119.117259_bib55","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/bi991328b","article-title":"Mutagenesis of E477 or K505 in the B\u2032 domain of human topoisomerase II beta increases the requirement for magnesium ions during strand passage","volume":"39","author":"West","year":"2000","journal-title":"Biochemistry"},{"key":"10.1124\/mol.119.117259_bib56","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0006-2952(02)00920-6","article-title":"Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells","volume":"63","author":"Willmore","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.119.117259_bib57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1124\/mol.54.1.78","article-title":"Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique","volume":"54","author":"Willmore","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.119.117259_bib58","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"key":"10.1124\/mol.119.117259_bib59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0748-5514(85)90028-5","article-title":"Doxorubicin-dependent lipid peroxidation at low partial pressures of O2","volume":"1","author":"Winterbourn","year":"1985","journal-title":"J Free Radic Biol Med"},{"key":"10.1124\/mol.119.117259_bib60","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2400960X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2400960X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.119.117259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:31:20Z","timestamp":1739961080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X2400960X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0026895X2400960X"],"URL":"https:\/\/doi.org\/10.1124\/mol.119.117259","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.119.117259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}